Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.

Abstract: The present invention relates to a method of obtaining altered plasmid contents in bacteria, bearing mutation in at least one of the chromosomal genes, nusG, rho, and dnaC, and the bacterial strains thereof, having the mutated chromosomal genes, individually or in various possible combinations, capable of altering the level of plasmids.

Abstract: The present invention provides a protein having ?1,2-fucosyltransferase activity, a DNA encoding the protein, a recombinant DNA comprising the DNA, a transformant comprising the recombinant DNA, a process for producing the protein having ?1,2-fucosyltransferase activity using the transformant, and a process for producing a fucose-containing complex carbohydrate using the transformant.

Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp2, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp2 polypeptides.

Abstract: The present invention relates to cell-regulatory proteins and to nucleotide sequences encoding said proteins wherein the proteins have been found to be potential tumor and/or senescense markers useful for medical diagnostics and additionally having therapeutical potential as well as antiapoptotic properties useful for improving cell viability in cell culture technology. The invention further relates to antibodies directed against the cell-regulatory proteins and to their use in medical diagnostics and therapy. The invention further relates to methods for the manufacture and application of the cell-regulatory proteins and of the corresponding nucleotide sequences.

Abstract: This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities.

Abstract: Methods are provided for producing an expression vector. In the subject methods, donor and acceptor vectors are combined in the presence of a recombinase to produce an expression vector that includes a first and second recombinase recognition site oriented in the same direction, wherein the first and second recombination sites are able to recombine with each other. In the subject methods, one of the donor and acceptor vectors includes a single recombinase recognition site while the other includes two recombinase recognition sites. Also provided are compositions for use in practicing the subject methods, including the donor and acceptor vectors themselves, as well as systems and kits that include the same. The subject invention finds use in a variety of different applications, including the transfer or cloning of a nucleic acid of interest from a first vector into one or more expression vectors, etc.

Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.

Abstract: The present invention relates to a method of obtaining altered plasmid contents in bacteria, bearing mutation in at least one of the chromosomal genes, nusG, rho, and dnaC, and the bacterial strains thereof, having the mutated chromosomal genes, individually or in various possible combinations, capable of altering the level of plasmids.

Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.

Abstract: An isolated WT1 interacting protein having the amino acid sequence as set forth in SEQ ID NO: 2, or an isolated protein that has an amino acid sequence in which one or a plurality of amino acids have been substituted, deleted, inserted, and/or added is functionally equivalent to the protein having the amino acid sequence as set forth in SEQ ID NO: 2; and comprises the amino acid sequence from Glu at position 449 to Met at position 541 in SEQ ID NO: 2.

Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.

Abstract: The present invention relates to an RNA polymerase I transcription factor TIF-IA and proteins related thereto, whose concentration and/or activity are correlated with the cell proliferation rate, and to DNA sequences encoding these proteins. The present invention also concerns ligands binding to an RNA polymerase I transcription factor TIF-IA and proteins related thereto, respectively, antagonists as well as antisense RNAs and/or ribozymes, directed against the TIF-IA expression. These compounds are of use for the prevention or treatment of diseases associated with an increased or reduced cell proliferation.

Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.

Abstract: The invention relates to gene transfer into human T cells using novel retroviral scFv cell targeting vectors and using these vectors for the treatment of T-cell-associated diseases.

Abstract: The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences.

Abstract: Nucleic acid molecules that encode plant proteins involved in photoperiodism and circadian rhythms are disclosed. These molecules may be introduced into plants in order to alter the photoperiodic and/or circadian clock-based gene expression of the plants.

Abstract: Five fluorogenic probe hydrolysis reverse transcriptase-polymerase chain reaction (RT-PCR) (TaqMan™) assays are described for serotype-specific detection of dengue 1–4 and group-specific detection of dengue viruses. Type- and group-specific oligonucleotide primers and fluorogenic probes were designed against conserved regions of the dengue genome. The invention provides TaqMan PCR assays, which are rapid, sensitive, and specific screening and serotyping tools for the epidemiological study of dengue infections.

Abstract: Compositions and methods are provided for identifying novel therapeutic agents for the treatment of cancer and other cellular proliferative disorders.